Email UpdatesSAMHSA recognizes the challenges posed by the current COVID-19 situation and is providing the following guidance on the provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency for Opioid Treatment Programs.
Source
Substance Abuse and Mental Health Services Administration
File Size
201 KB KB
Year
Format
Fact Sheet/Brochure
Terms of Use
Public domain
Topic
Clinical Guidelines
COVID-19
Medication Considerations
Audience
Medical Providers
Behavioral Health Providers
States
Resource Type
PDF
Use
Implementation of Substance Use Treatment in Ambulatory Care
Special Collection
MAT Tools and Resources